Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gentongping capsule is a Traditional Chinese Medicine (TCM) oral formulation developed and manufactured by Dalian Aosen Pharmaceutical through its subsidiary, Dalian Mingsen Pharmaceutical. It is primarily indicated for the treatment of cervical spondylosis and lumbar disc herniation, specifically targeting symptoms such as neck and shoulder pain, limb numbness, and restricted physical movement. The formulation is based on TCM principles of promoting blood circulation, removing blood stasis, and dredging meridians to alleviate pain. It typically contains a complex blend of herbal ingredients, including *Radix Puerariae* (Kudzu root), *Radix Angelicae Sinensis* (Dang Gui), and *Flos Carthami* (Safflower). It is an approved pharmaceutical product in China, categorized as a finished formulation for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gentongping capsule.